Advertisement
U.S. markets closed

ReproCELL Incorporated (4978.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
142.00+6.00 (+4.41%)
As of 03:15PM JST. Market open.
Full screen
Add
Comparison
Indicators
Technicals
Corporate Events
Mountain
DrawTable View
Settings
AllAllFavoritesTextStatisticsTechnicalsFibonacciMarkingsLines
Loading interactive chart...
1D
Date Range
Interval:
1 min
  • PR Newswire

    StemBioSys Announces Launch of CELLvo™ Atrial Cardiomyocyte, a Technological Leap Forward in Cardiotoxicity Screening

    StemBioSys, Inc. (StemBioSys) announced today the launch of CELLvo™ Atrial Cardiomyocyte, a "chamber specific" human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to function identically to human atrial cardiomyocytes. StemBioSys developed CELLvo™ Atrial Cardiomyocyte to empower pharmaceutical companies and academics with a more precise, efficient and cost-effective platform for screening new drug products in vitro for cardiotoxicity compared to animal models and other